FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer

Abstract

Background: Resistance to endocrine treatments is a major clinical challenge in the management of estrogen receptor positive breast cancers. Although multiple mechanisms leading to endocrine resistance have been proposed, the poor outcome of this subgroup of patients demands additional studies. Methods: FoxO3a involvement in the acquisition and reversion of tamoxifen resistance was assessed in vitro in three parental ER+ breast cancer cells, MCF-7, T47D and ZR-75-1, in the deriving Tamoxifen resistant models (TamR) and in Tet-inducible TamR/FoxO3a stable cell lines, by growth curves, PLA, siRNA, RT-PCR, Western blot, Immunofluorescence, Transmission Electron Microscopy, TUNEL, cell cycle, proteomics analyses and animal models. FoxO3a clinical relevance was validated in silico by Kaplan–Meier survival curves. Results: Here, we show that tamoxifen resistant breast cancer cells (TamR) express low FoxO3a levels. The hyperactive growth factors signaling, characterizing these cells, leads to FoxO3a hyper-phosphorylation and subsequent proteasomal degradation. FoxO3a re-expression by using TamR tetracycline inducible cells or by treating TamR with the anticonvulsant lamotrigine (LTG), restored the sensitivity to the antiestrogen and strongly reduced tumor mass in TamR-derived mouse xenografts. Proteomics data unveiled novel potential mediators of FoxO3a anti-proliferative and pro-apoptotic activity, while the Kaplan–Meier analysis showed that FoxO3a is predictive of a positive response to tamoxifen therapy in Luminal A breast cancer patients. Conclusions: Altogether, our data indicate that FoxO3a is a key target to be exploited in endocrine-resistant tumors. In this context, LTG, being able to induce FoxO3a, might represent a valid candidate in combination therapy to prevent resistance to tamoxifen in patients at risk.

Bortezomib-Loaded Mesoporous Silica Nanoparticles Selectively Alter Metabolism and Induce Death in Multiple Myeloma Cells

“…Cells were plated in GM for 24 h and, after 1 h MSNs treatment, shifted to fresh GM medium. After 36 h, cells were lysed as previously described [ 65 ]. Briefly, harvested cells were incubated (10 min on ice) with cytoplasmic buffer containing 1 M sucrose, 1 M Hepes, 1 M KCl, 1 M MgCl2, 1 M EDTA, 1 M EGTA, Digitonin 10% and 200 mM PMSF.…”

Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers

“…FOXO3a inhibition leads to breast cancer carcinogenesis [ 132 ]. FOXO3a overexpression is a desirable factor for prognosis, and its downregulation occurs in drug-resistant breast cancer cells [ 133 ]. Increasing evidence demonstrates that FOXO3a is a down-stream target of Akt [ 134 , 135 , 136 ].…”

CircRNAs in anticancer drug resistance: recent advances and future potential

“…Bioinformatic analysis indicated that circ_0025202 may act as a miRNA sponge. Further experiments proved that circ_0025202 can upregulate FOXO3a, an inhibitor of TAM resistance in BC [ 173 ], by sponging miR-182-5p, leading to reversion of TAM resistance. Liang et al [ 174 ] identified a novel circRNA, circBMPR2, as a suppressor of TAM resistance in BC.…”